VivoSim Labs (VIVS) Stock Overview
A pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
VIVS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
VivoSim Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$21.96 |
| 52 Week Low | US$1.41 |
| Beta | 1.27 |
| 1 Month Change | -18.97% |
| 3 Month Change | -41.07% |
| 1 Year Change | -65.53% |
| 3 Year Change | -89.20% |
| 5 Year Change | -98.77% |
| Change since IPO | -99.53% |
Recent News & Updates
Recent updates
Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?
Feb 10
Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation
Aug 24We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely
May 10We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely
Jan 04Shareholder Returns
| VIVS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.5% | -2.0% | -1.0% |
| 1Y | -65.5% | 23.0% | 14.9% |
Return vs Industry: VIVS underperformed the US Biotechs industry which returned 22.9% over the past year.
Return vs Market: VIVS underperformed the US Market which returned 14.7% over the past year.
Price Volatility
| VIVS volatility | |
|---|---|
| VIVS Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VIVS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VIVS's weekly volatility has decreased from 38% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 13 | n/a | vivosim.ai |
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.
VivoSim Labs, Inc. Fundamentals Summary
| VIVS fundamental statistics | |
|---|---|
| Market cap | US$4.90m |
| Earnings (TTM) | -US$1.98m |
| Revenue (TTM) | US$140.00k |
Is VIVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIVS income statement (TTM) | |
|---|---|
| Revenue | US$140.00k |
| Cost of Revenue | US$4.57m |
| Gross Profit | -US$4.42m |
| Other Expenses | -US$2.44m |
| Earnings | -US$1.98m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | -3,160.71% |
| Net Profit Margin | -1,416.43% |
| Debt/Equity Ratio | 5.0% |
How did VIVS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 10:13 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
VivoSim Labs, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lavin | BTIG |
| Caroline Corner | Cantor Fitzgerald & Co. |
| Jose De Jesus Haresco | Citizens JMP Securities, LLC |